Johan Maertens Selected Research

Transplantation

5/2022	Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
1/2022	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
1/2022	Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
12/2021	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group.
1/2021	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT).
1/2021	Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2021	Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis.
6/2020	Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.
11/2019	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
1/2019	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johan Maertens Research Topics

Disease

40	Aspergillosis 04/2021 - 11/2002
36	Infections 12/2022 - 12/2004
36	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2022 - 01/2007
32	Neoplasms (Cancer) 06/2022 - 09/2004
28	Mycoses (Diseases, Fungus) 12/2020 - 09/2005
24	Leukemia 05/2022 - 10/2003
22	Graft vs Host Disease (Graft-Versus-Host Disease) 03/2022 - 10/2003
16	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2022 - 01/2007
16	Invasive Fungal Infections 12/2021 - 09/2005
12	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2022 - 06/2005
11	Neutropenia 09/2022 - 01/2006
11	Invasive Pulmonary Aspergillosis 01/2022 - 12/2009
9	Communicable Diseases (Infectious Diseases) 01/2022 - 11/2006
8	Fever (Fevers) 01/2017 - 09/2005
7	Hematologic Neoplasms (Hematological Malignancy) 07/2019 - 12/2004
5	Febrile Neutropenia 01/2022 - 06/2006
5	Hematologic Diseases (Blood Diseases) 12/2021 - 12/2009
4	Cytomegalovirus Infections (Inclusion Disease) 09/2022 - 04/2011
4	Pulmonary Aspergillosis 01/2022 - 12/2004
4	Critical Illness (Critically Ill) 01/2022 - 11/2011
4	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2021 - 06/2005
4	Refractory Anemia 01/2020 - 09/2009
4	Multiple Myeloma 11/2019 - 10/2003
4	Mucositis 01/2017 - 02/2008
3	Toxoplasmosis 03/2022 - 01/2005
3	COVID-19 01/2022 - 12/2021
3	Lymphoma (Lymphomas) 12/2021 - 07/2003
3	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 01/2019
3	Mucormycosis 06/2020 - 01/2017
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 10/2014
3	Acquired Immunodeficiency Syndrome (AIDS) 01/2019 - 09/2005
3	Bronchiolitis Obliterans Syndrome 01/2019 - 01/2018
2	Viremia 09/2022 - 01/2019
2	Breakthrough Infections 01/2022 - 04/2010
2	Atrial Fibrillation 02/2021 - 12/2017
2	Pathologic Complete Response 01/2021 - 12/2011
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2019 - 06/2005
2	Aplastic Anemia (Anemia, Hypoplastic) 11/2015 - 11/2013
2	Stomatitis 09/2015 - 03/2008
2	Pneumonia (Pneumonitis) 09/2015 - 04/2009
2	Body Weight (Weight, Body) 05/2013 - 03/2008

Drug/Important Bio-Agent (IBA)

20	galactomannanIBA 01/2022 - 11/2002
12	Pharmaceutical PreparationsIBA 12/2022 - 12/2004
11	Voriconazole (Vfend)FDA LinkGeneric 10/2021 - 04/2009
9	posaconazole FDA Link 10/2021 - 01/2007
9	Sodium Glutamate (Accent)IBA 01/2019 - 06/2008
9	Caspofungin (Cancidas)FDA Link 04/2012 - 06/2003
7	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 01/2005
6	Phosphotransferases (Kinase)IBA 01/2022 - 06/2005
6	liposomal amphotericin B FDA Link 12/2021 - 05/2007
6	Biomarkers (Surrogate Marker)IBA 12/2020 - 01/2009
6	Cytarabine (Cytosar-U)FDA LinkGeneric 03/2017 - 04/2008
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 09/2005
5	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2021 - 07/2015
4	polyglucosanIBA 01/2021 - 11/2011
4	letermovirIBA 10/2020 - 12/2017
4	EnzymesIBA 01/2016 - 09/2004
3	maribavirIBA 09/2022 - 04/2011
3	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2022 - 01/2016
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 12/2019
3	TriazolesIBA 04/2021 - 12/2006
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2016
3	AzolesIBA 06/2020 - 07/2015
3	SteroidsIBA 01/2019 - 11/2002
3	EchinocandinsIBA 11/2013 - 12/2006
3	Itraconazole (Sporanox)FDA LinkGeneric 04/2007 - 09/2005
2	Valganciclovir FDA Link 09/2022 - 01/2019
2	glasdegibIBA 08/2022 - 01/2022
2	ChemokinesIBA 01/2022 - 01/2022
2	Cefepime (Maxipime)FDA LinkGeneric 01/2022 - 11/2020
2	Antiviral Agents (Antivirals)IBA 01/2022 - 12/2018
2	ruxolitinibIBA 01/2021 - 12/2019
2	fludarabineIBA 01/2021 - 01/2016
2	Calcineurin InhibitorsIBA 01/2021 - 01/2019
2	Melphalan (Alkeran)FDA LinkGeneric 01/2021 - 03/2008
2	EltanexorIBA 01/2021 - 11/2020
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 11/2009
2	Imatinib Mesylate (Gleevec)FDA Link 01/2021 - 06/2005
2	isavuconazoleIBA 06/2020 - 01/2017
2	terminaseIBA 01/2019 - 12/2018
2	GlucansIBA 01/2019 - 03/2011
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2018 - 10/2014
2	Micafungin (FK463)FDA Link 07/2015 - 05/2013
2	Amphotericin B (Amphotericin)FDA LinkGeneric 03/2015 - 04/2009
2	AntigensIBA 01/2013 - 04/2009

Therapy/Procedure

51	Therapeutics 09/2022 - 12/2004
41	Transplantation 05/2022 - 12/2004
32	Hematopoietic Stem Cell Transplantation 01/2022 - 11/2006
32	Stem Cell Transplantation 01/2021 - 07/2003
22	Drug Therapy (Chemotherapy) 08/2022 - 07/2003
15	Cell Transplantation 06/2022 - 05/2012
4	Salvage Therapy 07/2020 - 06/2006
4	Homologous Transplantation 01/2019 - 10/2003
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 05/2020 - 01/2016
3	Organ Transplantation 01/2019 - 12/2004
3	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 01/2018 - 12/2011
2	Biological Therapy 05/2022 - 01/2022
2	Haploidentical Transplantation 01/2018 - 01/2017
2	Remission Induction 01/2017 - 06/2012
2	Consolidation Chemotherapy 03/2014 - 12/2011